Statin Therapy in the Treatment of Sepsis

• Status: Completed
• Trial end date: 2010-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Simvastatin will attenutat IL-6 levels and lead to a more rapid shock reversal than placebo

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Beth Israel Deaconess Medical Center
• Treatments: Simvastatin

Criteria

Inclusion Criteria:

• Greater than 18 years old

• Hypotensive requiring vasopressors

• Suspected Infection

Exclusion Criteria:

• Pregnant

• Liver Failure (ALT or AST > 120)

• Rhabomyolysis (CPK > 3x normal)

• Comfort care measures status

• Chronic Liver Disease (Cirrhosis)

• Use of Cyclosporin, Digoxin, Statins

• Patients who are unable to take medications by mouth or NGT